FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)

View source ↗

Summary

FDA approved Amgen's supplemental application for Sensipar (cinacalcet hydrochloride).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease Related Secondary Hyperparathyroidism
• Hypercalcemia Associated with Parathyroid Carcinoma

Drugs mentioned

• SENSIPAR (CINACALCET HYDROCHLORIDE)

Snippet

SUPPL AP for SENSIPAR (CINACALCET HYDROCHLORIDE)